CHEK2 and prostate carcinoma: However, given that the CHEK2 p.E239K variant is known in breast and prostate cancer and has been shown to have an intermediate effect on protein function in functional yeast-based studies, and that TIAM1 p.R1053C and EWSR1 p.A327D showed promising results in the in silico studies, we proceeded to explore the possibility of all three genes targeting functionally related pathways, thus acting as combined drivers of carcinogenesis in the studied NMTC family.